ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. (PubMed, Vaccine) - "Vaccine receipt, female sex at birth, older age, and region may affect reactogenicity."

Journal • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Pain

HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - P2/3 | N=5404 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Phase classification: P2b ➔ P2/3

Phase classification • Human Immunodeficiency Virus • Infectious Disease